The authors have described a subregion of the hamster hypothalamic suprachiasmatic nucleus (SCN) containing cells that are immunopositive for the cytosolic calcium-binding protein, Calbindin-D 28K (CaBP). Several lines of evidence indicate that this region may constitute the site of the pacemaker cells that are responsible for the regulation of circadian locomotor rhythms. First, 79% of the CaBP-immunoreactive (ir) neurons express Fos in response to photic stimulation, indicating that they are close to or part of the input pathway to pacemakers. Second, at the light microscopy level, retinal terminals innervate the CaBP subnucleus. Finally, destruction of this subnucleus renders animals arrhythmic in locomotor activity. In this study, the authors examined the ultrastructural relationship between cholera toxin (CTβ) labeled retinal fibers and the CaBP-ir subregion within the hamster SCN. CTβ-ir retinal terminals make primarily axo-somatic, symmetric, synaptic contacts with CaBP-ir perikarya. In addition, retinal terminals form synapses with CaBP processes as well as with unidentified profiles. There are also complex interactions between retinal terminals, CaBP perikarya, and unidentified profiles. Given that axo-somatic synaptic input has a more potent influence on a cell's electrical activity than does axo-dendritic synaptic input, cells of the CaBP subregion of the SCN are ideally suited to respond rapidly to photic stimulation to reset circadian pacemakers.Keywords calcium-binding proteins; calbindin-D 28K ; CaBP; pacemaker; suprachiasmatic nucleus; retinal terminals; electron microscopy; circadian rhythmsThe suprachiasmatic nucleus (SCN) of the hypothalamus is the site of the putative circadian clock in mammals (see Klein et al., 1991). The circadian system regulates the periodicity of many rhythmic responses in mammals including rest-wake cycles (see Moore-Ede et al., 1982), electrical activity, and neuropeptide levels (Inouye, 1996), to name a few. In the absence of exogenous stimuli, the circadian clock oscillates with a periodicity that is close to 24 h. The circadian timing system also has the capacity to entrain or synchronize the organism to the exogenous geo-solar cycle. The primary neural substrate responsible for the © 2000 Sage Publications, Inc.Correspondence to: Maria-Teresa Romero. transduction of exogenous photic stimuli is the retinohypothalamic tract (RHT), a monosynaptic pathway projecting from the retina to the SCN (Card and Moore, 1991;Moore, 1996). A secondary pathway, the geniculo-hypothalamic tract, also provides photic input to the circadian pacemaker. Photic information is integrated in the SCN to produce a stable phase relationship between physiological and behavioral activity and the environmental light-dark cycle (Meijer, 1991). While it is clear that the SCN is the site of the circadian pacemaker, the precise identity of retinorecipient cells that mediate entrainment remains to be elucidated. NIH Public AccessWe recently described cells immunopositive for Calbindin-D 28K (...

Multiple mechanisms mediate the effects of estrogen in the central nervous system, including signal transduction pathways such as protein kinase A, protein kinase C, and phosphatidylinositol 3-kinase (PI3K) pathways. Previously we demonstrated that estrogen regulates a number of PI3K-related genes in the hypothalamus, including the PI3K p55gamma regulatory subunit. We hypothesized that PI3K activation is critical for the effects of estrogen and that the p55gamma subunit may be more prevalent than the p85alpha regulatory subunit in the hypothalamus. Therefore, in the present study, we compared the mRNA distribution of the p55gamma and p85alpha regulatory subunits by using in situ hybridization in guinea pig. Expression level of p55gamma mRNA was greater than p85alpha in most hypothalamic nuclei. Twenty-four hours of estrogen treatment increased p55gamma mRNA expression in the paraventricular, suprachiasmatic, arcuate, and ventromedial nuclei, and little or no change was observed for p85alpha mRNA. Quantitative real-time PCR confirmed the in situ hybridization results. Next, we investigated the general role of PI3K signaling in the estrogen-mediated changes of arcuate proopiomelanocortin (POMC) neuronal excitability by using whole-cell recording. One cellular mechanism by which estrogen increases neuronal excitability is to desensitize (uncouple) gamma-aminobutyric acid type B (GABA(B)) receptors from their G-protein-gated inwardly rectifying K(+) channels in hypothalamic neurons. We found that the PI3K inhibitors wortmannin and LY294002 significantly reduced the estrogen-mediated GABA(B) receptor desensitization in POMC arcuate neurons, suggesting that PI3K signaling is a critical downstream mediator of the estrogen-mediated rapid effects. Collectively, these data suggest that the interplay between estrogen and PI3K occurs at multiple levels, including transcriptional and membrane-initiated signaling events that ultimately lead to changes in homeostatic function.

Estrogen receptors can activate transcription in the nucleus, and activate rapid signal transduction cascades in the cytosol. Multiple reports identify estrogen receptors at the plasma membrane, while others document the dynamic responses of estrogen receptor to ligand binding. However, the function and identity of membrane estrogen receptors remain controversial. We have used confocal microscopy and cell fractionation on the murine hippocampus-derived HT22 cell line and rat primary cortical neurons transfected with estrogen receptor-green fluorescent protein constructs to address the membrane localization of these receptors. We observe translocation of estrogen receptor beta (beta) to the plasma membrane 5 min after exposure to 17beta-estradiol, whereas estrogen receptor alpha (alpha) localization remains unchanged. Membrane localization of estrogen receptor beta is transient, selective for 17beta-estradiol, and is not blocked by ICI182,780. Inhibition of the mitogen-activated protein kinase pathway does not block estrogen-mediated estrogen receptor beta membrane translocation, and in fact prolongs membrane localization. These data suggest that while both estrogen receptor alpha and estrogen receptor beta can be present at the neuronal membrane, their presence is differentially regulated.

Numerous preclinical studies suggest that gonadal steroids, particularly estrogen, may be neuroprotective against insult or disease progression. This paper reviews the mechanisms contributing to estrogen-mediated neuroprotection. Rapid signaling pathways, such as MAPK, PI3K, Akt, and PKC, are required for estrogen's ability to provide neuroprotection. These rapid signaling pathways converge on genomic pathways to modulate transcription of E2-responsive genes via ERE-dependent and ERE-independent mechanisms. It is clear that both rapid signaling and transcription are important for estrogen's neuroprotective effects. A mechanistic understanding of estrogen-mediated neuroprotection is crucial for the development of therapeutic interventions that enhance quality of life without deleterious side effects.

No abstract

Although most agree that 17β-estradiol is neuroprotective via a variety of mechanisms, less is known about the role that biological sex plays in receptor-mediated estradiol neuroprotection. To address this issue we isolated primary cortical neurons from rat pups sorted by sex and assessed the ability of estradiol to protect the neurons from death induced by glutamate. Five minute pretreatment with 10 to 50nM 17β-estradiol protected female but not male neurons from glutamate toxicity 24 hours later. Both estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) are expressed in these cultures. Experiments using an ERα selective agonist or antagonist indicate that this receptor is important for neuroprotection in female cortical neurons. The ERβ selective agonist conveys a small degree of neuroprotection to both male and female cortical neurons. Interestingly, we found that 17α estradiol and the novel membrane estrogen receptor (mER) agonist STX, but not bovine serum albumin conjugated estradiol or the GPR30 agonist G1 were neuroprotective in both male and female neurons. Taken together these data highlight a role for ERα in sexually dimorphic neuroprotection.

Prion diseases such as Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy in cattle, and scrapie in sheep are fatal neurodegenerative diseases for which there is no effective treatment. The pathology of these diseases involves the conversion of a protease sensitive form of the cellular prion protein (PrPC) into a protease resistant infectious form (PrPsc or PrPres). Both in vitro (cell culture and cell free conversion assays) and in vivo (animal) studies have demonstrated the strong dependence of this conversion process on protein sequence homology between the initial prion inoculum and the host’s own cellular prion protein. The presence of non-homologous (heterologous) proteins is often inhibitory to this conversion process. We hypothesize that the presence of heterologous prion proteins from one species might therefore constitute an effective treatment for prion disease in another species. To test this hypothesis, we infected mice intracerebrally with murine adapted RML-Chandler scrapie and treated them with heterologous prion protein (purified bacterially expressed recombinant hamster prion protein) or vehicle alone. Treated animals demonstrated reduced disease associated pathology, decreased accumulation of protease-resistant disease-associated prion protein, with delayed onset of clinical symptoms and motor deficits. This was concomitant with significantly increased survival times relative to mock-treated animals. These results provide proof of principle that recombinant hamster prion proteins can effectively and safely inhibit prion disease in mice, and suggest that hamster or other non-human prion proteins may be a viable treatment for prion diseases in humans.

Premature and long-term ovarian hormone loss following ovariectomy (OVX) is associated with cognitive impairment. This condition is prevented by estradiol (E 2 ) therapy when initiated shortly following OVX but not after substantial delay. To determine whether these clinical findings are correlated with changes in synaptic functions, we used adult OVX rats to evaluate the consequences of short-term (7-10 d, OVX Control ) and long-term (ϳ5 months, OVX LT ) ovarian hormone loss, as well as subsequent in vivo E 2 treatment, on excitatory synaptic transmission at the hippocampal CA3-CA1 synapses important for learning and memory. The results show that ovarian hormone loss was associated with a marked decrease in synaptic strength. E 2 treatment increased synaptic strength in OVX Control but not OVX LT rats, demonstrating a change in the efficacy for E 2 5 months following OVX. E 2 also had a more rapid effect: within minutes of bath application, E 2 acutely increased synaptic strength in all groups except OVX LT rats that did not receive in vivo E 2 treatment. E 2 's acute effect was mediated postsynaptically, and required Ca 2ϩ influx through the voltage-gated Ca 2ϩ channels. Despite E 2 's acute effect, synaptic strength of OVX LT rats remained significantly lower than that of OVX Control rats. Thus, changes in CA3-CA1 synaptic transmission associated with ovarian hormone loss cannot be fully reversed with delayed E 2 treatment. Given that synaptic strength at CA3-CA1 synapses is related to the ability to learn hippocampus-dependent tasks, these findings provide additional insights for understanding cognitive impairment-associated long-term ovarian hormone loss and ineffectiveness for delayed E 2 treatment to maintain cognitive functions.